CA19-9 and CK immunohistochemical expression in pancreatic and ampulla of vater carcinomas (A clinicopathological study

Background: Pancreatic carcinoma is one the most lethal malignancies and the Prognosis for patients with locally advanced or metastatic disease is poor. The 5-year survival rate is about 4%, which is the lowest of any cancer and median survival is 6 months. The high mortality rate is largely due to...

Full description

Bibliographic Details
Main Authors: Sudad A. Khalf, Kifah H. Abdulghafour
Format: Article
Language:English
Published: Faculty of Medicine University of Baghdad 2014-10-01
Series:مجلة كلية الطب
Subjects:
Online Access:http://iqjmc.uobaghdad.edu.iq/index.php/19JFacMedBaghdad36/article/view/508
id doaj-cb794971af8a4b67ac76c7f4171e3505
record_format Article
spelling doaj-cb794971af8a4b67ac76c7f4171e35052020-11-25T00:44:52ZengFaculty of Medicine University of Baghdadمجلة كلية الطب0041-94192410-80572014-10-0156310.32007/med.1936/jfacmedbagdad.v56i3.14CA19-9 and CK immunohistochemical expression in pancreatic and ampulla of vater carcinomas (A clinicopathological studySudad A. Khalf0Kifah H. Abdulghafour1Dept. of pathology, Alkadhemia Teaching Hopsital.Dept. of pathology, College of Medicine, Baghdad University. Background: Pancreatic carcinoma is one the most lethal malignancies and the Prognosis for patients with locally advanced or metastatic disease is poor. The 5-year survival rate is about 4%, which is the lowest of any cancer and median survival is 6 months. The high mortality rate is largely due to the typically advanced stage of the cancer at the time of diagnosis and treatment. Resection is the only current treatment resulting in cure for pancreatic carcinoma. However, due to the initiation and progression of this cancer without symptoms, only about 10% to 15% of patients present with localized disease amenable to potentially curative resection. Chemotherapy increases survival and up to date, the use of palliative chemotherapy is increasing due to the availability of more drugs and a wider range of indications. CA 19–9 is the marker most widely used clinically as elevated in approximately 75% of patients with pancreatic carcinoma with reported sensitivities ranging from 70% to 90% and specificities ranging from 68% to 91% with great support of CK marker in excluding or confirm diagnosis. Objectives:  Evaluation of CA19-9 and CK HMW markers expression in pancreatic and ampulla of vater carcinoma immunohistochemically & to correlate the immunohistochemical expression of CA19-9 and CK HMW markers with carcinoma location. Material and method:-  36 samples of whipple operations and partial pancreatectomy whom already diagnosed as pancreatic carcinoma from 2009-2013 whom visit and admitted to GIT hospital in Baghdad medical city. A tissue sample block from mass that already processed and identified by dissection report from data base of histopathology Lab was collected for staining by immunohistochemical method with C19.9 and CK marker. Results:-36 patients - 24 male and 12 females, Mean age (45+2.02) range (28-65) year with Male: Female ratio is (2:1) As differentiation of malignant cell in this study it was higher level with grade II (60%)  For TNM classification the result was dominantly staging as T3. IHC staining of CK19-9:-in present study we have 75% of patient samples with positive result. .Present study show that 4 patient's samples of total 6 positive CK/IHC staining was pancreatic carcinoma while only 2 of total positive was ampulla carcinoma.   Conclusion:-CA19-9 is pancreatic tumor associated marker but cannot used for screening and association with clinical findings. Meanwhile CK tissue immunolabling  mostly helpful in diagnosis of ampullary and pancreatic carcinoma and CK immunohistochemical staining can be used as exclusion aid in diagnosis of pancreaticcarcinoma. http://iqjmc.uobaghdad.edu.iq/index.php/19JFacMedBaghdad36/article/view/508whipple', pancreatic carcinoma, ampullary carcinoma CA19-9, CK.
collection DOAJ
language English
format Article
sources DOAJ
author Sudad A. Khalf
Kifah H. Abdulghafour
spellingShingle Sudad A. Khalf
Kifah H. Abdulghafour
CA19-9 and CK immunohistochemical expression in pancreatic and ampulla of vater carcinomas (A clinicopathological study
مجلة كلية الطب
whipple', pancreatic carcinoma, ampullary carcinoma CA19-9, CK.
author_facet Sudad A. Khalf
Kifah H. Abdulghafour
author_sort Sudad A. Khalf
title CA19-9 and CK immunohistochemical expression in pancreatic and ampulla of vater carcinomas (A clinicopathological study
title_short CA19-9 and CK immunohistochemical expression in pancreatic and ampulla of vater carcinomas (A clinicopathological study
title_full CA19-9 and CK immunohistochemical expression in pancreatic and ampulla of vater carcinomas (A clinicopathological study
title_fullStr CA19-9 and CK immunohistochemical expression in pancreatic and ampulla of vater carcinomas (A clinicopathological study
title_full_unstemmed CA19-9 and CK immunohistochemical expression in pancreatic and ampulla of vater carcinomas (A clinicopathological study
title_sort ca19-9 and ck immunohistochemical expression in pancreatic and ampulla of vater carcinomas (a clinicopathological study
publisher Faculty of Medicine University of Baghdad
series مجلة كلية الطب
issn 0041-9419
2410-8057
publishDate 2014-10-01
description Background: Pancreatic carcinoma is one the most lethal malignancies and the Prognosis for patients with locally advanced or metastatic disease is poor. The 5-year survival rate is about 4%, which is the lowest of any cancer and median survival is 6 months. The high mortality rate is largely due to the typically advanced stage of the cancer at the time of diagnosis and treatment. Resection is the only current treatment resulting in cure for pancreatic carcinoma. However, due to the initiation and progression of this cancer without symptoms, only about 10% to 15% of patients present with localized disease amenable to potentially curative resection. Chemotherapy increases survival and up to date, the use of palliative chemotherapy is increasing due to the availability of more drugs and a wider range of indications. CA 19–9 is the marker most widely used clinically as elevated in approximately 75% of patients with pancreatic carcinoma with reported sensitivities ranging from 70% to 90% and specificities ranging from 68% to 91% with great support of CK marker in excluding or confirm diagnosis. Objectives:  Evaluation of CA19-9 and CK HMW markers expression in pancreatic and ampulla of vater carcinoma immunohistochemically & to correlate the immunohistochemical expression of CA19-9 and CK HMW markers with carcinoma location. Material and method:-  36 samples of whipple operations and partial pancreatectomy whom already diagnosed as pancreatic carcinoma from 2009-2013 whom visit and admitted to GIT hospital in Baghdad medical city. A tissue sample block from mass that already processed and identified by dissection report from data base of histopathology Lab was collected for staining by immunohistochemical method with C19.9 and CK marker. Results:-36 patients - 24 male and 12 females, Mean age (45+2.02) range (28-65) year with Male: Female ratio is (2:1) As differentiation of malignant cell in this study it was higher level with grade II (60%)  For TNM classification the result was dominantly staging as T3. IHC staining of CK19-9:-in present study we have 75% of patient samples with positive result. .Present study show that 4 patient's samples of total 6 positive CK/IHC staining was pancreatic carcinoma while only 2 of total positive was ampulla carcinoma.   Conclusion:-CA19-9 is pancreatic tumor associated marker but cannot used for screening and association with clinical findings. Meanwhile CK tissue immunolabling  mostly helpful in diagnosis of ampullary and pancreatic carcinoma and CK immunohistochemical staining can be used as exclusion aid in diagnosis of pancreaticcarcinoma.
topic whipple', pancreatic carcinoma, ampullary carcinoma CA19-9, CK.
url http://iqjmc.uobaghdad.edu.iq/index.php/19JFacMedBaghdad36/article/view/508
work_keys_str_mv AT sudadakhalf ca199andckimmunohistochemicalexpressioninpancreaticandampullaofvatercarcinomasaclinicopathologicalstudy
AT kifahhabdulghafour ca199andckimmunohistochemicalexpressioninpancreaticandampullaofvatercarcinomasaclinicopathologicalstudy
_version_ 1725272851399835648